0001193125-26-210310
SEC filingNeumora Therapeutics reported Q1 2026 financial results with reduced R&D and G&A expenses, a net loss of $53.5 million, and $147.1 million in cash supporting operations into Q3 2027, alongside pipeline progress.
Neumora Therapeutics announced its first quarter 2026 financial results, showing meaningful cost reductions that narrowed the net loss to $53.5 million from $68.0 million in the prior year period. Research and development expenses declined 26% to $38.6 million, driven by lower clinical trial costs and personnel-related expenses, reflecting disciplined execution amid pipeline advancement. General and administrative expenses fell 24% to $14.3 million, also due to reduced personnel costs. CEO Paul L. Berns highlighted steady progress, including full enrollment in the navacaprant KOASTAL-2 and -3 studies for major depressive disorder, with joint topline data anticipated in Q2 2026 from over 450 optimized patients. The balance sheet remains robust with $147.1 million in cash and equivalents as of March 31, 2026, sufficient to fund operations into Q3 2027 without near-term dilution risk. Pipeline momentum continues with NMRA-511 advancing in Alzheimer's disease agitation after positive Phase 1b results showing strong effect size and favorable safety; multiple ascending dose data is due in H2 2026 ahead of a Phase 2 start in Q1 2027. NMRA-898's Phase 1 in schizophrenia and NMRA-215 for obesity are on track for H2 2026 updates and Q1 2027 clinic entry, respectively. These catalysts position Neumora to deliver multiple data readouts this year, potentially de-risking its novel neuroscience portfolio targeting underserved brain diseases.